Tags : biosimilar)


Fresenius Kabi Launches Idacio (biosimilar, adalimumab) for Multiple Chronic Inflammatory

Shots: Health Canada has authorized Idacio on Oct 30, 2020, for marketing in Canada and is now available for all indications of the reference (Humira) in the field of rheumatology, gastroenterology and dermatology Health Canada’s approval was based on analytical, pre/ clinical data that demonstrated similar PK, efficacy, safety and immunogenicity to the Humira. Idacio […]Read More